BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- CF AMR Syndicate awarded BioVersys up to £ 500,000 to support project addressing resistant non-tubercular mycobacteria (NTM) lung infections in people with cystic fibrosisLifeArc, Medicines Discovery Catapult and Cystic Fibrosis Trust to provide BioVersys with complementary disease specific supportBioVersys’ NTM program and candidates are derived from the company’s proprietary Ansamycin Chemistry platform and broadens our clinical and pre-clinical AMR pipeline BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme (CDP) award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

瑞士巴塞尔，2024年6月4日（环球通讯社）--CF AMR辛迪加授予BioVersys高达50万英镑的资金，用于支持解决囊性纤维化患者耐药性非结核分枝杆菌（NTM）肺部感染的项目LifeArc、药物发现弹射器和囊性纤维化信托基金，为BioVersys提供补充疾病特异性支持BioVersys的NTM计划和候选人来自该公司专有的安萨霉素化学平台，并拓宽了我们的临床和临床前AMR管道BioVersys AG，这是一家多资产、临床阶段的生物制药公司，专注于研究和开发新型抗菌产品，以治疗由多重耐药（“MDR”）细菌引起的严重危及生命的感染，今天宣布它通过LifeArc资助的合作发现计划（CDP）奖获得了CF AMR辛迪加的非稀释奖，最高可达50万英镑，支持针对囊性纤维化（CF）患者难以治疗的非结核分枝杆菌肺病（NTM-LD）的新型小分子的开发。

Antimicrobial resistance (AMR) is a major global health threat with the currently available therapeutics becoming more and more obsolete due to AMR.1 This is of greatest concern when addressing NTM-LD, as in chronic treatments (12-24 months) resistance can often develop. Due to the lack of effective treatment options, current cure rates for NTM-LD are as low as 30-50%.2 Particularly vulnerable to NTM-LD are people who suffer from structural airway disease such as cystic fibrosis (CF) or bronchiectasis.

抗菌药物耐药性（AMR）是全球健康的主要威胁，目前可用的治疗方法由于AMR而变得越来越过时。在解决NTM-LD时，这是最令人担忧的问题，因为在慢性治疗（12-24个月）中，耐药性经常会发展。由于缺乏有效的治疗选择，目前NTM-LD的治愈率低至30-50%。2患有结构性气道疾病如囊性纤维化（CF）或支气管扩张的人特别容易受到NTM-LD的影响。

CF affects over 162,000 people globally.3 While advances in drug treatment have transformed the experience of many people with the condition, there continues to be an urgent need to identify new therapi.

CF影响全球超过162000人。3虽然药物治疗的进步改变了许多患有这种疾病的人的经历，但仍然迫切需要确定新的治疗方法。